|
|
| COVID-19 amplified burdens for sponsors, CROs and sites, but especially for participants who faced increased costs and questions around getting to the clinic. |
| The clinical trial industry responded swiftly, adapting to the global shutdown with bold new ways to conduct trials. Automation has been key to success. |
| In fact, 84% of sponsors and CROs are actively seeking to increase the use of technology to better support decentralized trials. |
| When the catalyst of the pandemic wanes, we risk losing the progress we have made unless we collectively refuse to go back to the way things were before - and instead dedicate ourselves to implementing even more advancements and innovations that we've only dreamed of so far. |
- Why eClinical technology tools are crucial to delivering on patient and site centricity
- How integraing eCOA and payments can increase retention and improve compliance – the sponsor perspective
- What the considerations are for global implementation and localized requirements
|
| Start planning for the future of clinical trial conduct now to ensure that trials remain efficient, fast, reliable, and trusted. There is #NoGoingBack. |
